Saad Ahmad, MD
Ophthalmology · Elmhurst, ILNPI 1881613297
Payments from drug & device makers
Across 622 payments — averaging $102.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ocular Therapeutix, Inc.$20K
- Alimera Sciences, Inc.$13K
- Genentech USA, Inc.$7K
- AbbVie$7K
- Carl Zeiss Meditec USA, Inc.$4K
- Astellas Pharma US Inc$2K
- plus $10K from 27 others
What the payments were for
- Consulting fees$9,40925%
- Speaking & faculty fees$9,49126%
- Travel & lodging$3,1158%
- Food & beverage$10,64529%
- Education$1740%
- Other$4,23211%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ocular Therapeutix, Inc. | 7 | $20,441 |
| Alimera Sciences, Inc. | 95 | $13,139 |
| Genentech USA, Inc. | 81 | $7,144 |
| AbbVie(2 entities) | 127 | $6,878 |
| Carl Zeiss Meditec USA, Inc. | 2 | $4,232 |
| Astellas Pharma US Inc | 17 | $2,316 |
| ANI Pharmaceuticals, Inc. | 25 | $1,889 |
| Eyepoint US, Inc. | 12 | $1,800 |
| Novo Nordisk AS | 60 | $1,384 |
| Apellis Pharmaceuticals, Inc. | 69 | $1,208 |
| Regeneron Healthcare Solutions, Inc. | 24 | $701 |
| Alcon | 17 | $365 |
| Bausch & Lomb Americas Inc. | 17 | $343 |
| Mallinckrodt Hospital Products Inc. | 18 | $342 |
| Notal Vision, Inc. | 1 | $326 |
| Glaukos Corporation | 2 | $249 |
| Harrow Eye, LLC | 6 | $183 |
| Dutch Ophthalmic, USA | 1 | $172 |
| Spark Therapeutics, Inc. | 8 | $152 |
| Novartis | 10 | $129 |
| LKC Technologies, Inc. | 3 | $106 |
| Nova Eye, Inc. | 1 | $76 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $69 |
| Carl Zeiss Meditec, Inc. | 1 | $46 |
| Biotissue Holdings Inc. | 2 | $42 |
| Neurotech Pharmaceuticals, Inc. | 2 | $41 |
| Mallinckrodt Enterprises LLC | 2 | $36 |
| Astellas Pharma Global Development | 1 | $26 |
| NEW World Medical,inc. | 3 | $24 |
| Eyevance Pharmaceuticals LLC | 1 | $19 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $16 |
| Genentech, Inc. | 1 | $16 |
| Boston Scientific | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Iluvien$12,390
- SUSVIMO$5,798
- LUMERA 700$3,435
- YUTIQ$3,390
- Izervay$2,084
- IOLMaster 700$797
- Syfovre$272
- EVA, combined machine$172
- TISSUEBLUE$172
- iStent inject W$150
- IACCESS$150
- EYLEA HD$115
How this compares
$63,924 in reported general payments places this provider in the 90th percentile of 773 ophthalmology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Difluprednate | 818 | $95,404 |
| Bromfenac Sodium | 288 | $69,458 |
| ProlensaBromfenac Sodium | 145 | $53,383 |
| Brinzolamide | 281 | $44,539 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 71 | $14,269 |
| Dorzolamide Hcl | 489 | $8,435 |
| CombiganBrimonidine Tartrate/Timolol | 32 | $7,733 |
| RhopressaNetarsudil Mesylate | 16 | $5,830 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 56 | $5,365 |
| LumiganBimatoprost | 11 | $5,149 |
| RocklatanNetarsudil Mesylat/Latanoprost | 13 | $4,833 |
| Prednisolone Acetate | 124 | $4,005 |
| Gentamicin Sulfate | 145 | $998 |
| Ketorolac Tromethamine | 31 | $934 |
| Atropine Sulfate | 37 | $783 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $69 | $53,383145 claims |
| AlconSimbrinza | $365 | $14,26971 claims |
| AbbVieCombigan, Lumigan | $6,878 | $12,88243 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 773 ophthalmology providers in Illinois.
Other ophthalmology in Elmhurst
- Mateen AliniazeeElmhurst$122K
- Kevin KovachElmhurst$84K
- Donald SandersElmhurst$62K
- Veeral ShethOak Forest$14.8M
- Seenu HariprasadChicago$2.3M
- Lisa NijmSpringfield$1.9M
- Manjot GillChicago$1.4M
- Mitchell JacksonLake Villa$1.4M
- Ramanath BhandariSpringfield$1.2M
- Kathleen MornoNorth Riverside$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.